Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers

Yan Huang, Min Qi, Chengjin Liao, Jinrui Xun, Ju Zou, Haiyue Huang, Li-Yuan Long, Jun Chen, Xuegong Fan, Ruochan Chen, Yan Huang, Min Qi, Chengjin Liao, Jinrui Xun, Ju Zou, Haiyue Huang, Li-Yuan Long, Jun Chen, Xuegong Fan, Ruochan Chen

Abstract

Introduction: Hepatitis B virus (HBV) infection is associated with the onset of several major liver diseases. Inactive hepatitis B surface antigen (HBsAg) carriers (IHCs) may be successfully treated with PEGylated interferon-α2b (PEG-IFNα2b)-based antiviral therapy; however, studies on this treatment have been insufficient. In this study, we evaluated the efficacy and safety of PEG-IFNα2b treatment in IHCs.

Methods: Nineteen IHCs were treated with subcutaneous PEG-IFNα2b (180 μg/week) for 48 weeks (treatment group). Patients were followed up for 24 weeks after treatment discontinuation. Twenty untreated control patients were observed for 72 weeks (control group). HBsAg clearance (HBsAg < 0.05 IU/mL), HBsAg seroconversion, and alanine aminotransferase levels were monitored.

Results: Of the 19 patients treated with PEG-IFNα2b, 16 showed HBsAg loss (84.2%), and 13 showed HBsAg seroconversion (68.4%) at 72 weeks. All patients in the treatment group exhibited virological response (serum HBV DNA level < 10 IU/mL) at the time of drug withdrawal. In the control group, no patients experienced HBsAg loss during the observational period. There were no serious adverse events during treatment, and the therapy was well tolerated.

Conclusions: Short PEG-IFNα2b therapy in IHCs produced a high functional cure rate and good safety profile, suggesting that PEG-IFNα2b treatment may be the best choice for clinical cure of some IHCs.

Keywords: Functional cure; Hepatitis B surface antigen clearance; Inactive hepatitis B surface antigen carrier; PEGylated interferon-α2b.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Cumulative rate of hepatitis B surface antigen (HBsAg) loss and HBsAg seroconversion in treated patients

References

    1. Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Akinyemiju TF, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;4(11):1553–1568. doi: 10.1001/jamaoncol.2018.2706.
    1. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. doi: 10.1007/s12072-015-9675-4.
    1. Terrault NA, Lok A, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi: 10.1002/hep.29800.
    1. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut. 2008;57(1):84–90. doi: 10.1136/gut.2007.128496.
    1. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116(12):829–834. doi: 10.1016/j.amjmed.2003.12.040.
    1. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135(9):759–768. doi: 10.7326/0003-4819-135-9-200111060-00006.
    1. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35(6):1522–1527. doi: 10.1053/jhep.2002.33638.
    1. Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int. 2007;1(2):311–315. doi: 10.1007/s12072-007-9002-9.
    1. Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138(5):1747–1754. doi: 10.1053/j.gastro.2010.01.042.
    1. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36(11):2416–2420. doi: 10.3899/jrheum.081324.
    1. Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11(4):209–219. doi: 10.1038/nrgastro.2013.216.
    1. Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol. 2020;14(7):565–578. doi: 10.1080/17474124.2020.1774364.
    1. Li MH, Xie Y, Zhang L, et al. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. World J Hepatol. 2016;8(15):637–643. doi: 10.4254/wjh.v8.i15.637.
    1. Cao Z, Liu Y, Ma L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017;66(4):1058–1066. doi: 10.1002/hep.29213.
    1. Chinese Society of Hepatology et al. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Zhonghua Gan Zang Bing Za Zhi. 2015;23:888–905.
    1. Han M, Jiang J, Hou J, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study. Antivir Ther. 2016;21(4):337–344. doi: 10.3851/IMP3019.
    1. Hu P, Shang J, Zhang WH, et al. HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study. Zhonghua Gan Zang Bing Za Zhi. 2018;26(10):756–764.
    1. Mouzannar K, Liang TJ. Hepatitis B virus—recent therapeutic advances and challenges to cure. J Hepatol. 2020;73(3):694–695. doi: 10.1016/j.jhep.2020.04.015.
    1. Wu D, Yan WM, Tan DM. Combination of NA, Peg-IFN α-2b and GMCSF enhanced HBsAb production in NA suppressed CHB patients (The Anchor A study): an interim analysis. Hepatology. 2018. Abstract(oral) 157.
    1. Li GJ, Yu YQ, Chen SL, et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother. 2015;59(7):4121–4128. doi: 10.1128/AAC.00249-15.
    1. Switch or add-on PEGINTEREERON to chronic hepatitis B patients already on nucleos(t)ide analogue (SWAP study): final results. J Hepatol. 2019. AASLD2019, Abstracts-oral193.
    1. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–174. doi: 10.1056/NEJMoa013215.
    1. Huo TI, Wu JC, Lee PC, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology. 1998;28(1):231–236. doi: 10.1002/hep.510280130.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj